ArticleFrontiers in immunology2025
The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transarterial Chemoembolization Combined with Regorafenib and PD-1 Inhibitor as Second-Line Therapy for Unresectable Hepatocellular Carcinoma.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aimed to evaluate the effectiveness and safety of sintilimab versus camrelizumab, both plus targeted drugs, for advanced hepatocellular carcinoma (HCC) in the real world. Then the effectiveness was compared between sintilimab-lenvatinib and camrelizumab-apatinib. Methods: Patients diagnosed as advanced HCC were included from January 2017 to December 2023. They were concurrently treated with targeted drugs and sintilimab or camrelizumab. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were assessed. The subgroups analysis of PFS and OS based on baseline characteristics and univariate and multivariate COX analysis were done to test for heterogeneity of data and correct for confounding factors. Then subgroup analysis of sintilimab-lenvatinib versus camrelizumab-apatinib was conducted. Results: A total of 300 eligible HCC patients (199 in sintilimab group and 101 in camrelizumab group) were included in our study. No significant difference in PFS (p=0.47) and OS (p=0.51) was observed between sintilimab and camrelizumab groups. The median PFS (mPFS) was 262 days in sintilimab group, and 220 days in camrelizumab group, and neither group has reached the median OS. There was no difference in AEs between two groups also. The effect of sintilimab and camrelizumab on PFS and OS based on baseline characteristics was consistent with primary outcomes, except for other metastatic sites and lenvatinib in terms of OS. Multivariable Cox analysis identified the number of metastatic sites ≥2 and AFP level ≥400ng/mL as independent predictors of shorter PFS and OS, but they had no effect on the primary outcomes. In subgroup analysis, the PFS and OS of sintilimab -lenvatinib and camrelizumab-apatinib in first-line treatment of advanced HCC were not clinically different, although sintilimab-lenvatinib had a longer mPFS (301 days in sintilimab-lenvatinib group vs. 194 days in camrelizumab-apatinib group). Conclusions: Sintilimab and camrelizumab, both plus targeted agents, have equal clinical effectiveness and incidences of AEs. The effectiveness of sintilimab-lenvatinib and camrelizumab-apatinib are similar in first-line treatment of advanced HCC, despite a slight superiority in sintilimab-lenvatinib is observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.